Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial

被引：0
|
作者：
Badri, Nabeel
Zittel, Jason
Baran, Andrea M.
Dotan, Efrat
Hubbard, Joleen M.
Noel, Marcus Smith
Hezel, Aram F.
Tejani, Mohamedtaki Abdulaziz
Mohile, Supriya Gupta
机构：
[1] Univ Rochester Med Ctr, Wilmot Canc Inst, Rochester, NY USA
[2] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA
[3] Mayo Clin Rochester, Rochester, MN USA
[4] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC USA
[5] AdventHlth Canc Inst, Orlando, FL USA
[6] Univ Rochester Med Ctr, Rochester, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12047
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
    Xu, Donghao
    Liu, Yu
    Tang, Wentao
    Xu, Lingsha
    Liu, Tianyu
    Jiang, Yudong
    Zhou, Shizhao
    Qin, Xiaorui
    Li, Jisheng
    Zhao, Jiemin
    Ye, Lechi
    Chang, Wenju
    Xu, Jianmin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Regorafenib in refractory metastatic colorectal cancer: A multi-center retrospective study.
    Xu, Donghao
    Liu, Yu
    Tang, Wentao
    Xu, Lingsha
    Liu, Tianyu
    Li, Jisheng
    Zhao, Jiemin
    Ye, Le-Chi
    Xu, Jianmin
    Chang, Wenju
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15580 - E15580
  • [3] Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial
    Wang, Xiangling
    Li, Zhen
    Sha, Dan
    Ren, Haipeng
    Yi, Cuihua
    Li, Shuguang
    Wang, Peng
    Chu, Yunxia
    Wang, Jian
    Yang, Xiaorong
    Hao, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
    Liu, Rui
    Ji, Zhi
    Wang, Xia
    Zhu, Lila
    Xin, Jiaqi
    Ma, Lijun
    Zhang, Jiayu
    Ge, Shaohua
    Zhang, Le
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Duan, Jingjing
    Wang, Feixue
    Sun, Yansha
    Li, Hongli
    Deng, Ting
    Ba, Yi
    Hao, Jihui
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [5] Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
    Karasic, Thomas B.
    Brown, Timothy J.
    Schneider, Charles
    Teitelbaum, Ursina R.
    Reiss, Kim A.
    Mitchell, Tara C.
    Massa, Ryan C.
    O'Hara, Mark H.
    DiCicco, Lisa
    Garcia-Marcano, Luis
    Amaravadi, Ravi K.
    O'Dwyer, Peter J.
    ONCOLOGIST, 2022, 27 (09): : 716 - +
  • [6] PHASE 3 CORRECT TRIAL OF REGORAFENIB IN METASTATIC COLORECTAL CANCER (MCRC)
    Sobrero, Alberto
    Grothey, Axel
    Van Cutsem, Eric
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Barone, Carlo
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz Joseph
    Goldberg, Richard
    Sargent, Daniel
    Cihon, Frank
    Jeffers, Michael
    Wagner, Andrea
    Laurent, Dirk
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 16
  • [7] Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)
    Van Cutsem, Eric
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Barone, Carlo
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Sargent, Daniel J.
    Cihon, Frank
    Wagner, Andrea
    Laurent, Dirk
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
    Park, S.
    Ahn, H. K.
    Lee, S.
    Min, Y. J.
    Jung, H. A.
    Sun, J. -M.
    Lee, S-H.
    Ahn, J. S.
    Ahn, M. -J.
    Lee, J. B.
    Kim, S. M.
    Kim, H. R.
    Cho, B. C.
    Hong, M. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S149
  • [9] A multi-center, randomized, double-blind phase II trial of FOLFIRI plus regorafenib or placebo for patients with metastatic colorectal cancer who failed one prior line of oxaliplatin-containing therapy
    O'Neil, B.
    O'Reilly, S.
    Kasbari, S.
    Kim, R.
    McDermott, R.
    Moore, D.
    Grogan, W.
    Cohn, A.
    Bekaii-Saab, T.
    Ivanova, A.
    Olowokure, O.
    Fernando, N.
    McCaffrey, J.
    El-Rayes, B.
    Horgan, A.
    Ryan, T.
    Sherrill, G.
    Yacoub, G.
    Goldberg, R. M.
    Sanoff, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.
    Brown, Timothy J.
    Karasic, Thomas Benjamin
    Schneider, Charles John
    Teitelbaum, Ursina R.
    Reiss, Kim Anna
    Mitchell, Tara C.
    Massa, Ryan Campbell
    O'Hara, Mark H.
    DiCicco, Lisa
    Garcia-Marcano, Luis
    Amaravadi, Ravi K.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345